Denomab (Denosumab) is indicated for the:

• Treatment of postmenopausal women with osteoporosis at high risk for fracture.
• Treatment to increase bone mass in men with osteoporosis.
• Treatment of glucocorticoid-induced osteoporosis.
• Treatment of bone loss in men receiving androgen deprivation therapy for prostate cancer.
• Treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.